BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MediciNova\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MediciNova\, Inc.'s drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05464784-8091@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tipelukast: Phase 2 readout est. (NCT05464784)
DESCRIPTION:Tipelukast\, phase 2\, Type 2 Diabetes.\nStudy: MN-001 in Non-a
 lcoholic Fatty Liver Disease\, Type 2 Diabetes Mellitus\, and Hypertriglyc
 eridemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tipelukast#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05464784
URL:https://assetmemo.bio/drug/tipelukast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04057898-8762@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibudilast: Phase 2/3 readout est. (NCT04057898)
DESCRIPTION:Ibudilast\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: 
 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label E
 xtension for 6 Months in Patients With ALS\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibudilast
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040
 57898
URL:https://assetmemo.bio/drug/ibudilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
